Sensei Biotherapeutics, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues			0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold			0.0	0.0	0.0	0.0	0.0	0.0
Gross profit			0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]			40.6	37.0	36.0	31.5	30.6	22.1
Sales and marketing			37.1	33.5	32.6		28.1	17.8
General and administrative						3.5
Research and development						6.0
Other operating expenses			-37.2	-33.5	-32.6	-28.1	-28.1	-17.8
EBITDA [+]			-8.6	-8.6	-8.7	-8.7	-4.7	-10.1
EBITDA growth			85.2%	-14.5%	-39.6%	-52.9%
Depreciation and amortization			0.8	0.8	0.7	0.7	0.4	0.4
EBIT [+]			-9.4	-9.4	-9.4	-9.4	-5.1	-10.4
EBIT growth			85.0%	-10.0%	-35.7%	-49.8%
Non-recurring items [+]						0.0
Loss (gain) on sale of assets						0.0
Interest income, net [+]			0.0	0.0	0.0	0.0	0.4	0.1
Interest expense			0.3	0.3	0.3	0.3	0.1	0.1
Interest income			0.3	0.3	0.3	0.3	0.5	0.2
Other income (expense), net			-36.3	-32.6	-31.8	-27.4	-27.9	-17.9
Pre-tax income			-45.7	-42.0	-41.2	-36.8	-32.6	-28.2
Income taxes			0.0	0.0	0.0	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income			-45.7	-42.0	-41.2	-36.8	-32.6	-28.2

Basic EPS [+]			($1.53)	($1.40)	($1.38)	($1.37)	($1.59)	($2.14)
Growth			-4.2%	-34.3%	-64.7%	-89.5%
Diluted EPS [+]			($1.53)	($1.40)	($1.38)	($1.37)	($1.59)	($2.14)
Growth			-4.2%	-34.3%	-64.7%	-89.5%

Shares outstanding (basic) [+]			29.9	29.9	29.9	26.9	20.4	13.2
Growth			46.6%	126.2%	399.5%	1631.9%
Shares outstanding (diluted) [+]			29.9	29.9	29.9	26.9	20.4	13.2
Growth			46.6%	126.2%	399.5%	1631.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.